Edaravone suspension for oral administration
MYPI2025002966A0Undetermined Publication Date: 2020-05-02TANABE PHARMA CORP
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- MYPI2025002966
- Authority / Receiving Office
- MY · MY
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2018-11-02
- Filing Date
- 2019-11-01
- Publication Date
- 2020-05-02
Abstract
EDARAVONE SUSPENSION FOR ORAL ADMINISTRATION ABSTRACT This invention provides with an edaravone suspension for oral administration having excellent bioavailability. It is expected that burden on ALS patients and care workers can be reduced thereby.
Need to check novelty before this filing date? Find Prior Art
